TOMZ

This article first appeared on GuruFocus. Revenue: $2.25 million in Q2 2026, a 118% increase year-over-year and a 36% sequential increase from Q1 2026. Product Revenue: $1.86 million, up 185% year-over-year and 42% sequentially. Service Revenue: $389,000, up 13% sequentially and 3% year-over-year. Gross Profit: $1.39 million, up 105% year-over-year. Gross Margin: 61.7%, up from 50.3% in Q1 2026. Operating Expenses: $1.63 million, a 10% reduction year-over-year. Operating Loss: Approximately $244,000, improved 78% year-over-year. Net Loss: Approximately $382,000, or $0.05 per share, improved 69% year-over-year. Cash and Cash Equivalents: $322,000 at quarter end, up from $88,000 at December 31, 2025. Working Capital: $1.82 million, up from $1.02 million at year-end 2025. Stockholders' Equity: $1.43 million, up from $589,000. Applicator Sales: $355,000 in Q2 2026, up from $13,000 in Q2 2025. Backlog: $2.2 million at quarter end, expanding to $2.6 million post-quarter. Full-Year 2026 Revenue Guidance: Reaffirmed at least $12 million. Warning! GuruFocus has detected 6 Warning Signs with TOMZ. Is TOMZ fairly valued? Test your thesis with our free DCF calculator. Release Date: August 14, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. TOMI Environmental Solutions Inc (NASDAQ:TOMZ) reported a 118% year-over-year revenue increase in Q2 2026, with product revenue up 185%. The company achieved three consecutive quarters of growth, with a growing sales backlog reaching $2.6 million post-quarter. Gross margin improved to 61.7% in Q2 2026, up from 50.3% in Q1 2026, driven by higher revenue and a favorable product mix. Operating expenses decreased 10% year-over-year, and the operating loss improved by 78%, bringing the company closer to breakeven. The company secured new regulatory approvals, including an EPA label for AgriMist and EU registrations, expanding its market reach. Applicator sales surged to $355,000 in Q2 2026, up from $13,000 in Q2 2025, validating the razor-and-blade model. The company strengthened its balance sheet with working capital expanding to $1.82 million and cash increasing to $322,000. TOMI Environmental Solutions Inc (NASDAQ:TOMZ) is advancing its FDA 510(k) submission with the delivery of a new chamber to a Fortune 500 medical device manufacturer. The company has a robust sales pipeline of approximately $35 million, with $8.6 million in advanced stages expected to close in 2026. The pending merger with Carbonium Core includes a $10 million financing condition, which could transform the combined company's balance sheet. TOMI Environmental Solutions Inc (NASDAQ:TOMZ) still reported a net loss of $382,000 in Q2 2026, though improved from the prior year. The company incurred approximately $300,000 in elevated transaction-related expenses tied to the Carbonium Core merger, impacting profitability. Cash and cash equivalents remain low at $322,000, despite an increase from year-end 2025. The company's service revenue growth was modest, with only a 3% year-over-year increase, and was impacted by a production change at a large customer. The timeline for FDA 510(k) clearance remains uncertain, with studies still to be conducted and reported. The company's reliance on the equity line of credit and convertible notes highlights ongoing capital needs. The merger with Carbonium Core is subject to conditions, including raising $10 million, which may not be completed as planned. International revenue growth was slower at 62% year-over-year compared to US growth of 132%. The company's ability to achieve full-year revenue guidance of $12 million depends on closing advanced pipeline opportunities, which could be subject to customer budget shifts. The company's operating expenses, while reduced, still include significant professional and consulting fees that may continue in the near term. Q: What are the next milestones for the Carbonium Core merger, and what is the status of the $10 million financing condition? A: Dr. Halden Shane (CEO and Chairman) stated there are two levels of completion needed. First, regaining compliance with Nasdaq listing requirements, noting the stock has been above $1 for four weeks and shareholder equity is now over $3.3 million following note conversions. Second, raising the $10 million for the combined companies, which is still in negotiations. He also noted Carbonium Core's prototype is underway, with contracts with Oak Ridge Nuclear and the Department of Energy in final stages, which could generate revenue once the prototype produces graphite. Q: Can you provide more details on the timeline and path to profitability for TOMI? A: Niroshan Srirathan (Interim CFO) confirmed the company is on track to hit the $12 million revenue guidance for 2026, which will cover operating expenses and help achieve breakeven. He expects the company to hit breakeven comfortably by Q4, driven by revenue growth and continued cost-cutting measures. Q: Will the elevated professional and consulting fees continue in the coming quarters? A: Dr. Halden Shane (CEO) and Niroshan Srirathan (Interim CFO) explained that the approximately $300,000 in elevated fees this quarter were primarily tied to the Carbonium Core merger. Once the merger is completed, these professional fees are expected to decrease significantly. Q: Is the AgriMist offering included in the current sales pipeline, and will it add to future growth? A: Elissa Shane (COO) confirmed that the AgriMist potential is not included in the current pipeline figures. The newly granted EPA registration for AgriMist, which allows direct application to indoor grown plants and fruits up to the day of harvest, is expected to add to the pipeline as the company begins commercializing this product. Q: What are the next milestones for the FDA 510(k) medical device clearance, and what is the expected timeline? A: Elissa Shane (COO) stated that the next steps involve creating protocols, conducting studies, and reporting results to the FDA based on the recently delivered chamber to a Fortune 500 medical device manufacturer. She indicated it will take another quarter to provide a more accurate timeline, but the process is actively underway. Q: How would SteraMist be used in biodefense applications, and has the company explored opportunities with FEMA or the military? A: Dr. Halden Shane (CEO) explained that drones equipped with SteraMist units could decontaminate large pieces of military and non-military equipment aerially. Elissa Shane (COO) added that FEMA is a long-term customer with several foggers, and the Department of Health owns equipment for emergency response. However, the company has not yet explored specific naval applications, though the technology has been used in past Ebola outbreaks. Q: Can you provide more details on the hybrid system and its advantages? A: Elissa Shane (COO) explained that the hybrid system is a mix of the mobile fogger and permanent applicators, allowing customers to decide how and when to use the equipment. The strategy focuses on selling applicators and BIT Solution, which are the two essential components, giving customers flexibility to mix and match based on their budgets and facility-wide needs. Q: Have tariffs had any effect on TOMI's financials, and is the company paying any tariffs? A: Niroshan Srirathan (Interim CFO) stated he is not aware of any tariffs currently affecting the company and does not believe TOMI is paying any tariffs at this time. Q: Would an FDA ruling be required to get AgriMist approved for fresh produce and pre-bagged produce products? A: Elissa Shane (COO) clarified that the new EPA -4 label, combined with the FDA clearance received over a year ago for the CAS number of hydrogen peroxide, allows the company to cover both regulatory pathways. Facilities can choose to follow either the FDA ruling or the EPA label instructions, providing flexibility depending on which agency regulates them. Q: Has there been any progress in the ethylene oxide replacement market for medical instrument sterilization? A: Dr. Halden Shane (CEO) noted that many companies are looking to move away from ethylene oxide. The 510(k) submission process will help confirm the technology's ability to replace such chemicals. Once the 510(k) is obtained, these markets are expected to open up fairly quickly, as data from the major medical device manufacturer will be utilized to progress the submission. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Delivered three consecutive quarters of growth, with Q2 revenue increasing 118% year-over-year driven by strong demand for capital equipment and Custom Engineered Systems (CES). Validated the 'razor-and-blade' model as applicator sales surged 1,100% year-over-year, serving as a critical lead indicator for long-term recurring BIT Solution consumable demand. Achieved a 10% reduction in quarterly operating expenses through disciplined overhead management, despite elevated professional fees related to strategic merger activities. Strengthened the balance sheet via an equity line of credit and convertible note amendments, positioning the company to meet NASDAQ stockholders' equity requirements. Expanded the sales backlog to $2.6 million, demonstrating sustained demand even as existing orders are fulfilled across automated and integrated platforms. Advanced the technology platform with the delivery of the first fully designed SteraMist iHP chamber to a Fortune 500 medical device manufacturer, a key step for FDA 510(k) submission. Broadened market reach through new EPA registrations for AgriMist, authorizing direct application to indoor plants and fruits up to the day of harvest. Reaffirmed full-year 2026 revenue guidance of at least $12 million, supported by a $35 million commercial sales pipeline and $6.2 million in booked orders expected to complete by year-end. Anticipates reaching operating breakeven by Q4 2026 through a combination of revenue acceleration and the roll-off of one-time transaction costs. Focusing on the FDA 510(k) medical device pathway, with upcoming milestones centered on conducting and reporting validation studies with a major healthcare partner. Advancing a pending merger with Carbonium Core, which includes a $10 million minimum concurrent financing condition intended to transform the combined company's capital structure. Targeting expansion into the defense sector through new partnerships with the Defense Logistics Agency (DLA) and international defense contractors in Korea and Canada. Incurred approximately $300,000 in elevated advisory and legal costs during Q2 specifically tied to the Carbonium Core merger agreement. Effected a 1-for-3 reverse stock split on July 20, 2026, to support compliance with NASDAQ listing requirements. Implemented rigorous internal controls, including dedicated CPA oversight and formalized revenue recognition procedures, to remediate historic material weaknesses. Secured a new unconditional EPA registration for AgriMist, expanding the addressable market to include high-value food safety and cultivation applications. Management clarified that the current $35 million pipeline does not yet include potential revenue from the newly approved AgriMist offering. The AgriMist registration is expected to add incremental opportunities in the food safety and indoor cultivation sectors. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. The next phase involves establishing and conducting specific protocols and studies with a primary customer base now that equipment is installed. Management expects to provide a more definitive timeline for the regulatory process in the next quarterly update. Completion depends on two primary factors: maintaining NASDAQ listing compliance and successfully raising $10 million in concurrent financing. Carbonium Core is nearing final contract stages with Oak Ridge Nuclear and the Department of Energy, which will support their transition from prototype to revenue generation. Management believes the company is within 'striking distance' of breakeven, targeting Q4 2026 to reach this milestone. Profitability will be driven by hitting the $12 million annual revenue target while professional fees associated with the merger begin to subside. The hybrid system allows customers to mix mobile foggers with permanent applicators, providing flexibility for facility-wide use based on varying budgets. Applicators are now assembled in-house, improving supply chain control and supporting the high-margin recurring revenue model.

Company Delivers 118% Q2 Revenue Growth, Reaffirms Full-Year 2026 Guidance of $12 Million (113% YoY Growth) FREDERICK, Md., Aug. 14, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, today announced financial results for the three and six months ended June 30, 2026, and provided an update on strategic initiatives. Select financial and operational achievements for the quarter are as follows: Q2 Revenue Surges 118% Year-Over-Year to $2.25 Million; Sequential Revenue Increases 36% Over Q1 2026 Gross Profit More Than Doubles to $1.39 Million; Gross Margin Improves to 61.7% from 50.3% in Q1 2026 Reaffirms Full-Year 2026 Revenue Guidance of at Least $12.0 Million Definitive Merger Agreement Signed with Carbonium Core Secures Unconditional EPA Registration for SteraMist® (BIT®) – AgriMist across Post-Harvest Agriculture, Cannabis and Hemp Expands European Regulatory Footprint to 11 Countries; Advances NSF Certification Framework for Biosafety Cabinets Executive Commentary Dr. Halden Shane, CEO of TOMI Environmental Solutions commented, “The second quarter of 2026 was a defining operational and commercial period for TOMI, delivering our third consecutive quarter of accelerating growth, with year-over-year revenue growth of 118% to $2,247,000. Gross profit roughly doubled, and with strict cost control, the Company continues to work toward operating at breakeven on a cash basis.  We are very proud of these achievements.  We believe this performance reflects strong execution across our razor-and-blade commercial model, driven by surge demand for capital equipment, Custom Engineered Systems, and rapid adoption of our SteraMist applicators.” “From a strategic and technical perspective, we also made excellent progress.  We made critical advances across our technical, regulatory, and commercial pipelines. In the second quarter, we delivered custom SteraMist iHP chambers to a Fortune 500 medical device manufacturer—advancing our formal FDA 510(k) clearance process—while expanding our commercial sales pipeline to approximately $35 million ($8.6 million in advanced stages) and growing our backlog to $2.6 million post-quarter.” “On the regulatory front, our biocidal product registrations now span 11 European countries, and the EPA recently granted a new unconditional registration for AgriMist (-4 label), authorizing direct SteraMist application through the day of harvest across food safety, cannabis, and agriculture.  We are excited for the future of TOMI and look forward to providing additional updates in the near term.” Q2 2026 Highlights: Significant Revenue Acceleration: Q2 2026 revenue of $2,246,909 represented a 118% increase year-over-year versus Q2 2025 ($1,031,115) and a 36% sequential increase over Q1 2026 ($1,654,227), reflecting strong commercial momentum across mobile capital equipment and Custom Engineered System (CES) deployments. Six-month year-to-date revenue expanded 50% to $3,901,000 compared to $2,608,000 in the prior-year period. Strong Gross Profit: Gross profit more than doubled, increasing 105% to $1,385,306 compared to $677,124 in Q2 2025 and increasing 67% sequentially from $831,776 in Q1 2026, reflecting strong revenue growth and continued expansion of the Company's equipment, consumable, and service businesses. Strong Margin Profile: Gross margin improved to 61.7% for Q2 2026 from 50.3% in Q1 2026 and remained at a healthy level compared to 65.7% in Q2 2025, driven by strong equipment sales, higher revenue volume, and continued growth in consumable and recurring revenue streams. Applicator & Consumable Growth: Q2 2026 applicator sales reached $355,000 (up from $13,000 in Q2 2025), validating growing customer adoption of our razor-and-blade business model. Mid-year BIT™ Solution consumable sales exceeded $700,000, continuing to build a high-margin recurring revenue stream. Substantial Improvement in Operating Performance: Operating loss for Q2 2026 improved 78% to $(244,142) compared to $(1,132,689) in Q2 2025, demonstrating significant progress toward operating breakeven. Net loss for the second quarter of 2026 improved 69% to $(382,299), or $(0.05) per basic and diluted share, compared to $(1,237,516), or $(0.19) per basic and diluted share, for the second quarter of 2025. For the six-month period, net loss improved 20% to $(1,192,945) compared to $(1,493,109) in the prior-year period. Disciplined Cost Overhead: Total operating expenses for Q2 2026 declined 10% year-over-year to $1,629,448 (versus $1,810,000 in Q2 2025), reflecting sustained overhead discipline across general, administrative, and selling costs while continuing to invest in core business development. Strengthened Balance Sheet & Liquidity: Cash and cash equivalents reached $321,899 as of June 30, 2026, up from $87,775 at December 31, 2025. Shareholders’ equity improved significantly to $1,428,436 (up from $588,504 at year-end 2025), while working capital increased to $1,818,000 (up from $1,024,000 at year-end 2025), further strengthening liquidity and operational flexibility. Expanding Backlog & High-Value Sales Pipeline: Total sales order backlog expanded to $2.2 million as of June 30, 2026 (and has since increased to $2.6 million post-quarter). Booked orders and expected completions before year-end exceed $6.2 million, supporting an active integrated project pipeline (SIS, Hybrid, and CES) of $4.3 million across 13 projects and an overall commercial sales pipeline of approximately $35 million ($8.6 million in advanced stages). Financial Results for the three and six months ended June 30, 2026, compared to June 30, 2025 Sales, net was $2,246,909 compared to $1,031,115 for the three months ended June 30, 2026, and 2025, respectively, a 118% increase. Product revenue increased $1,205,000 (185%) to $1,858,000, driven by surge demand for capital equipment, Custom Engineered Systems (CES), and targeted SteraMist applicator adoption. Service revenue increased $11,000 (3%) to $389,000, supported by growing service provider rental activity and recurring decontamination service contracts. Geographic Performance: Domestic (U.S.) revenue increased 132% to $1,908,000 compared to $822,000 in Q2 2025. International revenue grew 62% to $339,000 compared to $209,000 in Q2 2025, supported by the onboarding of new customers in the UK. Gross Profit was $1,385,306, or 61.7% of net sales, for Q2 2026, compared to $677,124, or 65.7% of net sales, for Q2 2025. Gross profit increased 105% year-over-year and 67% sequentially from $831,776 in Q1 2026. The Company maintained a strong margin profile while benefiting from increased revenue volume, equipment sales, and continued growth in consumable and recurring service revenue. Total operating expenses were $1,629,448 for Q2 2026, a reduction of $180,365 or 10% compared to $1,809,813 in Q2 2025, reflecting disciplined overhead management and lower general and administrative costs, partially offset by increased professional and consulting expenses associated with strategic growth initiatives. Loss from operations was $(244,142) for Q2 2026, an improvement of $888,547 (78%) compared to $(1,132,689) for Q2 2025, demonstrating significant progress toward operating breakeven. Net loss was $(382,299), or $(0.05) per basic and diluted share for Q2 2026, compared to a net loss of $(1,237,516) or $(0.19) per basic and diluted share for Q2 2025. Sales order backlog stood at $2.2 million as of June 30, 2026 (expanding to $2.6 million post-quarter), supporting an active integrated project pipeline (SIS, Hybrid, and CES) of $4.3 million across 13 projects and providing strong visibility into second-half revenue conversion. Recent Business Highlights: On April 27, 2026, the Company reported strong interest in its solutions at INTERPHEX 2026, engaging with over 200 current and potential customers and finalizing timelines with a prominent American healthcare company to develop an iHP integration for its proprietary premix container system. On April 29, 2026, the Company announced a major strategic pivot toward autonomous systems, targeting drone-enabled, robotic, and AI-powered SteraMist iHP decontamination across global transportation, defense, aviation, and maritime platforms. On April 30, 2026, the Company executed a non-binding letter of intent to merge with Carbonium Core, Inc., a U.S.-based producer of nuclear-grade graphite for advanced reactor technologies, with an implied enterprise valuation of $120 million. On May 7, 2026, the Company's Binary Ionization Technology received formal approval from four additional European Union member states, expanding total EU and UK regulatory authorizations to eleven countries. On May 27, 2026, the Company highlighted expanded commercial relevance for SteraMist amid rising global concerns tied to a CDC-published hantavirus study and escalating Ebola outbreak activity. On June 29, 2026, the Company signed a definitive Agreement and Plan of Merger with Carbonium Core, Inc., pursuant to which Carbonium stockholders will receive 19.99% of TOMZ common stock at closing plus Series C Preferred Stock convertible into 90% of the combined company upon shareholder approval, supported by a required $10 million concurrent financing transaction. On July 20, 2026, post-quarter, the Company effected a 1-for-3 reverse stock split of its Common Stock and Series A Preferred Stock to regain compliance with Nasdaq's $1.00 minimum bid price requirement. On August 3, 2026, post-quarter, the U.S. Environmental Protection Agency granted a new unconditional registration for SteraMist® (BIT®) – AgriMist (EPA Reg. No. 90150-4), expanding labeled use sites to include post-harvest food safety applications, cannabis and hemp cultivation, and greenhouse agriculture up to and including the day of harvest. Looking Ahead TOMI enters the second half of 2026 with strong commercial visibility, an expanding recurring revenue base, and a proposed corporate merger under way. The Company is executing a focused strategy to: Advance Proposed Merger: Complete the required $10 million concurrent financing and advance toward closing the definitive merger with Carbonium Core, Inc., subject to regulatory and stockholder approvals. Drive Recurring Revenue: Accelerate year-over-year recurring revenue through increased BIT™ Solution sales, expanding applicator adoption, and growing iHP Corporate Service contracts across healthcare and industrial sectors. Convert Commercial Pipeline & Backlog: Deliver on our $2.5 million sales backlog and convert key opportunities within our $35 million commercial sales pipeline ($8.6 million in advanced stages), including integrated SIS, Hybrid, and Custom Engineered System deployments. Advance High-Value Technical & Regulatory Pathways: Progress our FDA 510(k) medical device clearance submission, capitalize on the new EPA AgriMist label expansion in agricultural and food safety markets, and leverage 11 EU/UK regulatory authorizations to capture European cleanroom and life sciences demand. Expand Defense & Institutional Sales: Scale distribution channels across defense and public health sectors by leveraging our Defense Logistics Agency (DLA) distribution authorization and expanding international partner networks across Europe, Canada, Latin America, and Asia. Conference Call Information TOMI will hold a conference call to discuss Second Quarter 2026 results at 4:30 p.m. ET today, August 14, 2026. To participate in the call by phone, dial (888) 506-0062 approximately five minutes prior to the scheduled start time and provide participant access code 709299 or request the "TOMI Environmental Solutions second quarter earnings call." International callers please dial (973) 528-0011. To access the live webcast or view the press release, please visit the Investor Relations section of the TOMI website or register at the following link:https://www.webcaster5.com/Webcast/Page/2262/54403 A replay of the teleconference will be available until August 21, 2026, and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use replay access code: 54403. A replay of the webcast will be available for at least 90 days on the company’s website, starting approximately one hour after the completion of the call. TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at [email protected]. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management's judgment, beliefs, current trends and anticipated business and market conditions. These forward-looking statements include, without limitation, statements regarding the proposed merger between TOMI Environmental Solutions, Inc. ("TOMI") and Carbonium Core, Inc. ("Carbonium"), including the anticipated timing and completion of the transaction, expected benefits to TOMI and its stockholders, anticipated growth opportunities, future business prospects, the commercialization and scaling of Carbonium's technology, anticipated financing activities, expected market demand for nuclear-grade graphite and other critical materials, and TOMI's expectations regarding future revenue growth, backlog conversion, business development initiatives, international expansion, operational performance and financial results, including the statements under the section entitled "Looking Ahead." The proposed merger remains subject to the satisfaction or waiver of customary closing conditions, including, among other things, completion of contemplated financing activities, regulatory and other approvals, continued compliance with applicable Nasdaq requirements, and other conditions set forth in the definitive merger agreement. There can be no assurance that the transaction will be completed on the anticipated terms, within the expected timeframe, or at all. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such statements. These risks include, but are not limited to, risks related to the completion of the proposed merger; the ability of the combined company to successfully execute its business strategy; the commercialization, development and scalability of Carbonium's technology and operations; the ability to obtain necessary financing; changes in market demand, competitive conditions, regulatory developments or economic conditions; TOMI's ability to acquire new customers, expand sales, maintain growth, convert backlog and pipeline opportunities into revenue, and improve operating performance; reliance on a limited number of products for a significant portion of revenues; and other risks described in TOMI's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The information provided in this press release is based on facts and circumstances known at the time of issuance. Actual results may differ materially from those anticipated due to a variety of factors, including those described above and other unknown or unpredictable factors. Although TOMI believes the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Readers are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements speak only as of the date of this press release, and TOMI undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law. The following represents our condensed consolidated balance sheets and statement of operations from our Quarterly Report on Form 10-Q for the three months ended June 30, 2026: All share and per share amounts presented in these condensed consolidated financial statements have been retroactively adjusted to reflect the Company's 1-for-3 reverse stock split, effective July 20, 2026 (see Note 9), unless otherwise indicated. The accompanying notes are an integral part of the condensed consolidated financial statements. All share and per share amounts presented in these condensed consolidated financial statements have been retroactively adjusted to reflect the Company's 1-for-3 reverse stock split, effective July 20, 2026 (see Note 9), unless otherwise indicated. The accompanying notes are an integral part of the condensed consolidated financial statements.

TOMI Environmental Solutions, Inc. (TOMZ) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This company is expected to post quarterly loss of $0.11 per share in its upcoming report, which represents a year-over-year change of +38.9%. Revenues are expected to be $1.84 million, up 78.6% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 16.67% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For TOMI Environmental Solutions, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%. On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination makes it difficult to conclusively predict that TOMI Environmental Solutions will beat the consensus EPS estimate. Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that TOMI Environmental Solutions would post a loss of$0.12 per share when it actually produced a loss of -$0.12, delivering no surprise. The company has not been able to beat consensus EPS estimates in any of the last four quarters. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. TOMI Environmental Solutions doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report TOMI Environmental Solutions, Inc. (TOMZ) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

-Carbonium Merger Remains on Track-European Regulatory Expansion and Partnership Growth-Advancement of Biosafety Cabinet Standards -Defense Sector Growth FREDERICK, Md., July 29, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today reaffirmed its expectation to achieve revenue of at least $12 million in 2026. This is driven by strong first half trends, an increase of over 100% in sales and receipt of sales as compared to 2025, which has already exceeded the full 2025 year sales. Currently TOMI has secured over $6.2 million in booked orders and orders that are expected to be completed before year-end. Further, approximately $8.6 million of the Company’s current $35 million sales pipeline is in advanced stages. The Company remains actively engaged with Carbonium Core following the signing of the definitive merger agreement, as we continue to work toward closing of the transaction in the second half of 2026. As previously announced, with the support of federal and state government, including the U.S. Department of Energy, Carbonium is conducting a pilot study to produce nuclear-grade graphite for 4th-generation nuclear reactors and plans to move to full-scale commercial production, and we look forward to the completion of the merger which we believe will significantly enhance the value and financial performance of our company. In the second quarter of 2026, all four key metrics, BIT Solution sales, mobile equipment sales, single applicator sales and support services, showed both year-over-year and sequential growth. The increases in applicator sales and support services are primarily due to initiatives implemented in late 2024 and early 2025. The Company continues to pursue new growth markets, including robotaxis, biosecurity, drones and humanoid robotics. International sales continue to be an expanding opportunity for the Company. TOMI’s innovative disinfection product is now approved for use in Austria, Italy, the Netherlands, Belgium, Denmark, Germany, Hungary, Spain, Great Britain, and Northern Ireland. We added in Switzerland through an amendment and anticipate receiving approvals in France, Switzerland, Ireland, Poland, Portugal, and Romania. TOMI’s recent expansion of SteraMist registrations across the European Union has significantly strengthened the Company’s established European network. In Poland, our partnership with MedLine will soon be able to successfully market SteraMist under the DeconLine brand once mutual recognition is approved. Additionally, TOMI has deepened its commercial pipelines through dedicated partners in Germany, the United Kingdom, and the Netherlands, many of whom bring well-established commercial, healthcare and military networks. TOMI’s long-term partner in Israel is also actively deploying SteraMist technology to support regional containment efforts in response to an active Ebola outbreak. In Puerto Rico, Integrated Services for Productivity and Validation (ISPV) is focused on driving adoption within the region’s strong life sciences and food manufacturing industries. In Argentina and surrounding markets, TOMI is collaborating with a new partner to pursue shared opportunities with major global accounts, including Pfizer, Fresenius Kabi, and Merck. This expansion complements the Company’s long-standing partnership with Bacteria Free in Chile, which is now extending its reach from life sciences into the food safety sector. NSF International (“NSF”) - an independent nonprofit organization of developed standards and certifies products for public health and safety - is rewriting the rules on Biosafety Cabinet (BSC) decontamination. TOMI played a key role in advancing discussion at the June 2026 meeting. The industry is shifting away from listing legacy known methods and brands, such as paraformaldehyde, and moving toward strict, performance-based criteria focused on efficacy, validation, and material compatibility areas where SteraMist iHP technology excels. Several high-quality opportunities within the pipeline underscore the strength of TOMI’s competitive positioning. These include a near-$1 million project initiated in Q2 involving the installation of four applicators per proprietary machine line at a major medical company, a large-scale opportunity now out for bid where our Canadian partners have secured access to supply eight Hybrid Systems, and a Custom Engineered System (“CES”) valued at approximately $1 million. TOMI continues to expand its presence in the defense sector, having recently received approvals from defense contractors in Korea and defense agencies in Canada. While confidentiality agreements limit the disclosure of specific details, these relationships represent multi-year efforts with significant long-term potential. The Company also remains actively engaged with key U.S. government agencies, including USAMRIID, NIH, Aberdeen, and others. In addition, TOMI, with a long-term representative of the company, will be helping implementation of a partnership with The Defense Logistics Agency (DLA), which manages the global defense supply chain for the U.S. military services and allied partners. This partnership is expected to streamline and accelerate government procurement of SteraMist iHP Techology. The Company will also be supporting the close of a pharmaceutical client who has received approvals for approximately $500,000 in SteraMist systems scheduled for delivery this year. TOMI’s Chief Operating Officer, Elissa J. (E.J.) Shane states, “We are pleased with the continued momentum across the SteraMist iHP business. With three consecutive quarters of growth, a quality pipeline, meaningful defense sector progress, and an expanding global partner network, TOMI is executing well on multiple fronts. We remain confident in the Company’s trajectory and believe we are well positioned for continued progress throughout the remainder of 2026 and beyond.” Dr. Halden Shane, Chairman and CEO of TOMI Environmental Solutions, commented, “This is an exciting period for our business and shareholders. In addition to the strong performance of TOMI’s business, the merger with Carbonium Core marks a strategic pivot into the high-growth nuclear materials sector, driven by demand from AI infrastructure and defense applications. Nuclear graphite is a critical, irreplaceable material for the future of clean energy, serving as a primary moderator, and structural component in next generation reactor design. It’s unique ability to withstand extreme temperature, provide structural stability, and efficiently slow down neutrons without absorbing them, makes it essential in obtaining nuclear chain reactions in advanced, safe, and efficient power systems. Demand for high purity nuclear graphite is accelerating rapidly due to the global push for decarbonization and energy security, with the International Energy Agency projecting that annual investment in nuclear projects will need to double to $120 billion by 2030”. For more information about SteraMist and TOMI Environmental Solutions, visit SteraMist.com. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at [email protected]. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to preliminary financial results, including preliminary revenue information, estimated open orders and sales pipeline, expected revenue growth in 2026 and beyond, the benefit of Carbonium merger; expectation with respect to Carbonium’s business operations; and the ability to TOMI to generate revenue in new and international markets. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These may include, but are not limited to, our ability to acquire new customers and expands sales; our projected revenue and revenue recognized from anticipated future purchase orders, invoiced orders, and contracts, our ability to maintain and manage growth and generate sales (equipment and consumable), our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT:John Nesbett/Zach NevasIMS Investor [email protected]

FREDERICK, Md., July 09, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today reported robust preliminary second-quarter 2026 results that demonstrate accelerating momentum in its high-margin razor-and-blade business model. The Company continues to expand its installed base of SteraMist iHP systems while generating recurring, high-margin revenue from BIT Solution and related consumables. Record Revenue MomentumTotal revenue for the second quarter reached approximately $2.3 million, representing a 124% increase year-over-year. Combined with open orders of $6.2 million, TOMI has already surpassed its full-year 2025 revenue, demonstrating the powerful scalability of its strategic initiatives across equipment, services, and consumables into different areas and expanding market presence.Key 2Q26 financial highlights include: Mobile Capital Equipment revenue surged 186% to $777,000 from $271,000 in the prior-year quarter. Accessories revenue increased 91% to $200,000 from $104,000 in the prior-year quarter. Support Services revenue increased 67% to $195,000 from $116,000 in the second quarter of 2025; including open orders, Support Services revenue has already surpassed the full-year 2025 total ($581,000 versus $346,000). Applicator sales increased to $355,000 from $13,000 in the prior-year quarter, validating the targeted SteraMist applicator initiative. BIT Solution revenue grew 35% to $304,000 from $224,000 in the prior-year quarter; including open orders, mid-year BIT Solution sales exceed $700,000. Gross margin expanded to 70% from 66% in the prior-year quarter. U.S. service provider rental activity increased 60% compared with all of 2025, driven by rising demand for flexible, on-demand iHP deployment amid heightened cleaning requirements and the need for rapid-response capabilities without large capital outlays. Industry-Leading RecognitionSteraMist was named the Disinfection and Decontamination Products Company of the Year for 2026, awarded by the Medical Tech Outlook. This marks back-to-back global victories for the SteraMist brand, reinforcing its absolute efficacy and tech-forward leadership across modern biosecurity sectors worldwide across pharmaceuticals, healthcare, life sciences, food, and emergency response. Expanding iHP Enclosure SolutionsTOMI has begun formally tracking a dedicated enclosure category as it scales delivery of iHP decontamination chambers. These advanced systems are now being deployed across medical device manufacturing, broader healthcare settings, and life sciences facilities. Working closely with leading global manufacturers, TOMI is delivering faster, safer, and more efficient decontamination alternatives that reduce cycle times and regulatory risk for both existing and new customers. NV+ Customized DeploymentThe newly launched NV+ system has been sold in a customized configuration to a major healthcare facility in Minnesota, with delivery scheduled for the third quarter. This landmark order highlights growing demand for TOMI’s flexible, facility-specific solutions and is expected to generate meaningful recurring revenue through ongoing BIT Solution and service contracts, further validating the Company’s automation strategy and expanding its footprint in the healthcare vertical. Strategic Customer ExpansionThe prominent American healthcare company that TOMI finalized a custom engineering contract with at INTERPHEX 2026 in April has expanded into a significantly larger automation project late in the quarter, with further phases expected throughout the year. Demand from U.S. departments of health and special pathogen units increased notably during the period, consistent with heightened national focus on public health preparedness and rapid-response capabilities for emerging pathogens. TOMI expanded its global reach by adding three new distributors covering the United States, South Africa, and Argentina, along with additional South American territories. These partners span life sciences and emergency services markets, extending the Company’s commercial footprint. Dr. Halden Shane, CEO of TOMI Environmental Solutions, commented, “The second quarter demonstrates the power of our razor-and-razor blade model in action. We have commercialized iHP technology across a full suite of offerings—from mobile capital equipment and fully automated, customized permanent systems to global service deployment. High-margin, recurring consumables such as BIT Solution and accessories continue to drive sustainable revenue this year. Our open orders have exceeded last year’s total revenue, signaling strong adoption and recurring demand. With a robust pipeline in automation and public health, we are expanding into new verticals while leveraging our proven economic model. This approach is consistent with companies like Gillette, Keurig and Hewlett Packard, along with others that monetize through installed bases and proprietary consumables”. For more information about SteraMist and TOMI Environmental Solutions, visit SteraMist.com. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.For additional information, please visit https://www.steramist.com or contact us at [email protected]. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to preliminary financial results, including preliminary revenue information, estimated open orders, BIT Solution sales, and estimated total integration pipeline, expected revenue growth in 2026 and beyond, TOMI’s products and services to serve the life sciences sector, and the ability to complete delivery of products and services pursuant to purchase orders. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These may include, but are not limited to, our ability to acquire new customers and expands sales; our projected revenue and revenue recognized from anticipated future purchase orders, invoiced orders, and contracts, our ability to maintain and manage growth and generate sales (equipment and consumable), our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT:  John Nesbett/Zach NevasIMS Investor Relations  [email protected]

Image source: The Motley Fool. Friday, May 8, 2026 at 4:30 p.m. ET Chief Executive Officer — Halden Shane Chief Financial Officer — David Vanston Chief Operating Officer — Elissa Shane Halden Shane: Thank you, Zach, and thank you for joining us for our 2025 earnings report today. I am pleased to share our full year 2025 results and more importantly, our perspective on where TOMI Environmental Solutions is headed. While 2025 was a year that tested our patience, it was also a year that validated our technology, deepened our customer relationships and positioned us to execute on a meaningful revenue opportunity in 2026 and beyond. I want to walk you through the highlights with optimism I generally feel as I review the progress our team has made. The SteraMist Integration System, which is our SIS platform, achieved its first commercial installation at a leading CDMO in June of 2025. The milestone proved our concept and by year-end, we had 4 fully operational SIS enclosure installations. We closed the year with a signed purchase contract of $500,000 for a global biopharmaceutical leader in December for integration into sterile manufacturing pass-through fill boxes. In the same month, a leading cell and gene therapy manufacturer adopted SteraMist iHP for a commercial scale pharmaceutical facility, a landmark win in one of the fastest-growing sectors of life sciences manufacturing. We were selected by NASA Johnson Space Center for a biosecurity operation, and they have continued to express satisfaction with our technology's performance. We deployed critical resources to support wildfire recovery efforts in the California communities, demonstrating both our civic commitment and our operational agility. We secured a bid from a leading university in Rhode Island for our CES technology. That project has been completed and awaits factoring testing. In the eye health sector, one of our most prominent new platinum customers onboarded in Q1 2025 has grown to 2 active facilities, each using 5 SteraMist machines for sterilization procedures. A third site in Berlin, Germany is set to commence trials in June of 2026. This customer also operates under an open monthly BIT Solution order, exactly the recurring revenue model we are building. Our OEM partnership strategy is gaining serious momentum. Relationships with PBSC, ESCO and Steelco are embedding iHP directly into clean room enclosures, pass-through hatches and biosafety cabinets at the point of manufacture, creating a scalable distribution channel that expands our reach without proportionately increasing our direct sales cost. We successfully completed our first collaboration project with partner PBSC, the iHP pass-through, which exceeded decontamination cycle speed expectations and generated strong customer feedback. We have already begun a second PBSC project. We expanded into the agriculture industry through our partnership with Algafeed, who has committed to acquiring additional handheld units before the end of 2026 in food safety. The FDA's late 2025 approval of hydrogen peroxide as a direct food additive for multiple uses, including as an antimicrobial and bleaching agent is a watershed regulatory moment for us. We are now engaged with significant partners, including Danone and Nestle and are actively winning bids, both directly and through service providers. SteraMist iHP is demonstrating real-world efficacy across a wide range of food processing environments. We are actively pursuing a food contract notification or FCN and have identified 2 specific opportunities to enhance our efforts on a tailored FCN for powdered infant formula, which comes at the request of an existing customer. Additionally, we are awaiting approval of our -4 label from the EPA for our cannabis industry and other requested markets in our Food Safety division. We also plan to submit a -5 EPA label based on the studies conducted with Plum Island as previously announced. A landmark USDA study confirmed BITs efficacy against the formed wing virus for agricultural biosecurity in honeybees. In 2025, SteraMist was honored with the Disinfection Decontamination Products Company of the Year Award by MedTech Outlook. We achieved compliance, recognition across 3 safety vendor management platforms and are in the process of adding a fourth to support 2 ongoing integration projects at a well-known Baltimore hospital. Our customer service team is actively transitioning our larger base to open order policies for support service offerings and BIT Solution orders. The backlog of our orders for support services is up 16%, and BIT Solution is up 24% in the first quarter of 2026 compared to the same period last year, providing early and compelling indicators of increasing recurring revenue trajectory we are building. To our long-term supporters of our technology and company, we are pleased to announce that we're finally receiving approvals from the HSE and the BPR submissions, we are now officially recognized in the United Kingdom, including Wales and Northern Ireland as well as in the Netherlands. The recent approval in the Netherlands strengthens our confidence that other EU countries will soon follow suit. Our heart monitoring device project is nearing completion and is scheduled for factory testing next month. We are preparing to introduce our iHP device to the U.S. markets through the appropriate regulatory pathways, including the FDA 510(k) premarket notification process once testing is finalized. The success of receiving the FDA 510(k) means that we'll finally be able to go after the entire ethylene oxide sterilization market. The global ethylene oxide market was a $5.29 billion market last year. Key growth factors is a rising demand for sterilized medical consumables and improved healthcare infrastructure, particularly for hospital, labs and surgery centers. Our technology is protected by more than 30 utility and design patents through 2038, and is deployed in over 40 countries. We are entering 2026 with operational momentum, growing recurring revenue and expanding global customer base and a clear strategy to drive sustainable growth. Our focus remains on execution, converting our pipeline into recognized revenue while continuing to advance the technology platform that makes all of this possible. The pipeline that we have is the strongest we've ever had. Our first quarter 2026 revenue is greater than our first quarter of 2025. I will discuss some details in my conclusion today, but our entire opportunity book for integration projects remains at $16 million. The entire SteraMist iHP opportunity book is currently at $20 million. However, first, I will now hand the call over to our Chief Financial Officer, David Vanston, who will provide an overview of the financial results for the full year ended December 31, 2025, compared to the same period in 2024. David? David Vanston: Thank you, Dr. Shane. I will now walk you through our full year '25 financial results. Our complete audited financial statements are included in the Form 10-K we filed with the SEC and in today's press release. Revenue for the year ended December 31, 2025, was $5.6 million compared to $7.7 million in '24. The decline was driven primarily by the timing of customer equipment purchases. Service revenue remained relatively stable year-over-year, which we view as an indicator of the durability of our installed base. Gross margin improved to approximately 55%, up from 46% in '24, reflecting lower cost of sales and a reduction of inventory reserves compared to the prior year. Total operating expenses were $6.9 million, down approximately 10% from '24, reflecting disciplined cost management. The net loss was $3.7 million or $0.19 per share, an improvement from a net loss of $4.5 million or $0.22 per share in 2024. We ended the year with approximately $88,000 in cash. Working capital was approximately $1 million, and we used $1.2 million in operating cash during '25, an improvement from $1.4 million in '24. We have taken steps to address our liquidity position, including a $535,000 convertible note raise during '25, a $20 million equity line of credit with Hudson Global Ventures entered into November '25, from which we have made our first draw approximately $94,000 in February '26. We've done an effective S3 shelf registration for up to $50 million, and we've engaged Bancroft Capital to explore additional financing options. I encourage investors to review our Form 10-K in full. I will now turn our call over to our Chief Operating Officer, Shane to discuss upcoming business highlights. Elissa Shane: Thank you, David. As Dr. Shane highlighted earlier in the call, we are actively focusing on open BIT Solution orders and annual service offerings, leading to a higher open sales book metric. This initiative stems from our growth in personnel and operations, along with our enhanced comprehensive training program that prioritizes continuous recertification. This strategy not only elevates customer standards for implementation and safety, but also has the potential to drive additional revenue and foster deeper product adoption in the future. The sales performance of support services and BIT Solutions sales are expected to exceed 2025 levels as evidenced by the increase of 16% in the backlog of orders for TOMI Support Services and an increase of 24% in BIT Solution backlog of orders for the first quarter of 2026 compared to the same period last year. Dr. Shane also provided updated information on 2025 announcements for just a handful of customers. This includes anticipated orders from our aquaculture customer, a completed Custom Engineered System, or CES, for the Rhode Island University, 2 iHP chambers for the biopharmaceutical partner, a second order with our partner in Malaysia, and a third location in Berlin, Germany for the eye health company, which we expect will proceed with the same standard operating procedures as the first 2 sites. We anticipate approximately $3 million in sales among these 5 customers and the trends in support services and BIT Solutions sales for 2026. It's important to note that this projected $3 million in revenue includes approximately $920,000 that overlaps with the $3 million integration pipeline announced on November 26, 2025. When factoring in our iHP deployment services, which generates over $1 million consistently, we can confidently state $6 million in revenue just among 5 customers and 3 revenue streams for 2026. To date, approximately $800,000 has been recognized from the November 2025 $3 million integration pipeline. This amount originates from 10 distinct customer orders. Of these 10, 7 customers have formally placed the order. We anticipate final approvals from the remaining 3 accounts, and we have added 4 more integration projects moving towards CapEx approvals since the November announcement, which is anticipated to contribute another $2.3 million to our active immediate integration project pipeline. Our East Coast distributor, ARES Scientific, has been instrumental in securing multiple university wins for our SIS platform. We're actively collaborating with VWR, Avantor, engaging with all case managers and overhauling marketing initiatives with them. We are prioritizing the ongoing education and engagement of our international partners, investing in them to promote their own long-term customer base instead of expanding into new regions. This strategic focus, coupled with recent regulatory approvals, is expected to support our growth and positively influence our revenue. For example, we have successfully received HSE approval and announced a preferred partnership with Total Clean Air, or TCA in the United Kingdom, where we recently completed factory testing on a custom engineered project that they brought to us. TCA has also invested in mobile equipment in quarter 1, 2026 to support their demonstration and service deployment capabilities. The food safety sector is also beginning to gain momentum, and we're receiving valuable referrals and case studies from our current clients. This industry uses our SteraPak product or requires custom applications, indicating that we are still in the early stages of realizing significant revenue. Additionally, there remains much work to be done on the regulatory front. For example, Nestle's pending expansion waits for other international registrations outside the ones received in the European Union. One of the most exciting developments comes from our long-standing relationship with Disinfectant Care, which has secured a service contract at a major dairy facility in Mexico. Following customer-specific testing and studies conducted on site, SteraMist iHP not only demonstrated its efficacy, but also showed the preservation of cheese quality, a key finding that strengthens our credibility and served as a valuable referral for other new customers. In summary, we are now making strides across a diverse range of sectors in the food industry. We are used in cheese, eggs, coffee, ice cream, consumer packaged goods, cannabis, nutrition, vertical farming, pet food, food ingredient suppliers, refrigerated foods and specialty ingredient suppliers. This is broadening of our market presence positions us well in the industry. Another significant area of focus for us, which we believe is expected to see returns in 2026 is the biological safety cabinet or BSC industry, particularly regarding our service providers and the SIS stand-alone system. We have developed the necessary accessories and protocols for treating all classes of cabinets, a progress required as we prepare for NSF approvals this summer. Currently, we have certified service providers utilizing our SteraMist iHP technology, including [ Triumvirate ] and MarathonLS on the East Coast as well as HEPA in Canada. On April 2, we conducted a key demonstration with one of the most recognized providers in the industry who operates multiple locations across the United States. Triumvirate hosted a webinar this quarter where they showcased how iHP technology outperforms key competitors in the market, including Spor-Klenz, Formaldehyde, and Vaporized Hydrogen Peroxide. This webinar was well attended attracting approximately 250 participants. Ultimately, our goal is to enable these service providers to compete effectively by incorporating iHP technology into their offerings for BSCs. They appreciate this innovation because it allows them to complete more treatments in a single day compared to older technologies. In addition, we maintain a robust intellectual property portfolio, CE and UL listings and are preparing to pursue USP 1072 material efficacy, which will expedite our sales process in the life sciences market. Furthermore, we are committed and continued to conduct customer-specific studies that help us secure contracts and maintain the client roster we hold, such as those highlighted today. I will now return the call back to our CEO, Dr. Halden Shane. Halden Shane: Thank you, EJ. I want to take a moment, maybe even more of a moment and express deep appreciation to the majority of our shareholders who supported us and have believed in our mission through our highs and lows. You are the majority and our long-term investors. Thank you for supporting our team and most importantly, believing in our technology and products. I believe at the start, we all knew this was not going to be easy because we're creating a new standard in many industries, and it's very hard to accomplish being undercapitalized makes it even harder. But we are on the verge of accomplishing the impossible. To the handful of naysayers, we believe we'll be able to earn your support, and we continue to execute a deliberate strategy to expand our operations and improve our financial performance. If not, then maybe it's the wrong company or you need to see a professional. It was a tough year for us from the financial perspective, but we remain focused the whole time on the future. In my eyes, there are no excuses, but were definitely roadblocks. Those roadblocks included DOGE, tariffs, working capital and recently the war. We chose to become the standard in the pharmaceutical, life science and university vivarium market. Unfortunately, some of the negatives of becoming a standard in that market is the perfect storm that occurred in 2025. Like there was panic buying behind the 2020 COVID, there was a lack of buying in the 2025 due to the reasons I stated above. Just recently received an e-mail from a major university that everybody knows on the West Coast of the United States. They were putting off a purchase until the end of 2026. The reason they had to postpone the purchase was because of DOGE, tariffs and political uncertainty, including the war. Also, that person stated there was an uncertainty maybe about her job. But no matter, we are a team, and we can overcome situations like that. And I can assure it's all temporary. The university will purchase this year even if it's a new professional in that job position. I did a review of our stock over the last 10 years. I choose certain points because it was approximately when we received our hospital health care EPA registration and had marketing in place. The key metrics are pretty amazing. In 2014, revenue was about $2.2 million. Our stock price was $2.16. Our major clients was a Panamanian hospital and a group in Mexico trying to sell to Mexican hospitals. In 2020, we had a banner year. Unfortunately, it was due to the pandemic. We did $25 million, demonstrated that we're capable of handling that volume of business. It did take away from the focus on the life science industry, pharmaceuticals, et cetera, but most of that was temporary panic buying. Our stock price was $4.57. In 2024, our revenue was approximately $7.7 million. Our client list was pretty impressive compared to 2014, and our stock price ended up at $1.05. The next year, 2025, our sales was $5.6 million. The sales that we could recognize as revenue, obviously, as you know, the sales were much higher, as we stated, provided in our pipeline with open significant orders for the first time moving across into 2026. As stated previously, we were confronted with tariffs, DOGE, political uncertainty. We closed the year with a stock price of $0.78. Now we're in 2026. It looks like our first quarter, which includes recognized revenue and open orders, could be $3 million or higher. Not sure how this ends up playing out later today. But for sure, we're beating our first quarter 2025 revenue in the first quarter of 2026. Our stock price is around $0.55. We estimate our revenue for this year will be around $12 million, bearing any unknowns. In 2020, we did a reverse split. Today, that $0.55 comes out to be about $0.0688 pre-split. So here's a short list of our current clients. Pfizer, Merck, Thermo Fisher, Fresenius Kabi, [ Allogene ], Boehringer Ingelheim, Catalent, CSL, [ Seqirus ], ITH Pharmaceuticals, Nestle Purina, Mead Johnson, [ Ziegler ], Simplot, Perdue AgriBusiness, Kindred Health, Mercy Health, Novant Health, St. Jude Children, Gila River Health Care, FDA, USDA, CDC, NIH, DHS, USAMRIID, [ Armitron ], ESCO, [ Telestar ], ServiceMaster, First Onsite, Avantor, Tecumseh. In retrospect, do you think a company like TOMI with that list is worth $0.0688 only? My point here is our stock price was $2.14 when we had 2 customers, 1 in Panama and 1 in Mexico. I remember a statement from a very successful person, Warren Buffett, "be greedy when others are fearful." That statement couldn't be true today about our company. I choose to run this company making a decision that many CEOs will never make. And that's because it hurts before it pays. I stop relying on easy sales and onetime equipment and build something from a more potent recurring control over how customers operate. The shift does not show up cleanly on quarterly charts. It shows up as a service revenue climbs and consumables replace capital purchases. Our customers stop buying, they start attending. That is where the game changes. We are not growing very fast, but we are growing very smart. Our company has moved from episodic revenue to embedded revenue before a deal closes, the relationship reset. Not every deployment creates a tail, more usage, more replacement, more service. This is not a product business anymore. It's a system. Recurring revenue isn't about stability. It's about control. Most executives say they want predictable revenue. What they actually want is predictable revenue without sacrifice. We took the hit upfront. Volatility increased, revenue looked uneven. Margins had to be rebuilt. But underneath the engine changed. Short-term policy facility is often the price of long-term dominance. Instead of building expensive infrastructure scale globally, we use distribution channels and partnerships to expand and reach without expanding costs. International revenue became a large slice of the pie without dragging down the balance sheet. That's not expansion. That's leverage we used. Scale without cost is the cleanest form of growth. At the same time, we wanted the business towards higher-margin solutions and service -- services. That's our razor-razor blade model, not louder, not last year, just better economics. The following current numbers could possibly change, but the point I want to make is that at this moment, our economics, of course, is first based on sales of equipment revenue, but our scaling and cleanest form of growth is solution sales, support service and iHP in-house service. Quarter 1 of 2025, we did $299,000 change in solution sales. In quarter 1 of 2026, at this moment, our solution sales are $429,413. As far as support services in quarter 1 of 2025, we had 73,279. Currently, in the first quarter of 2026, we have 253,390. In support services, these are such things as training, certifications, qualifications, validation cycle developments, installations, et cetera. And the third part, iHP service. In the first quarter of 2025, we had $439,386. Currently, with invoice and open orders, we have a total of $729,440. Margins improved, mix improved, the business became more resilient without announcing it. We were able to figure out how to achieve success by having money actually compound. Do you keep chasing revenue to reset every quarter? Or do you endure short-term pain to build revenue that compounds without permission. That decision defines whether you're playing offense or playing survival. We didn't eliminate risk. We repositioned it. In doing so, we created something more valuable than growth. We created dependency in a world chasing speed. We chose structure and structure wins. I can't take the credit for all this writing. I want to thank [ Joel Block ] for understanding how we have created this company and understanding the suffering we've gone through. Once again, I want to thank everyone for their long-term commitment and support and for a small team of 20 working endlessly to achieve all the goals. I also want to thank our creditors who've been super as we go through the stage of growth. At the end, the warriors that have helped us achieve success. Also, I'd like everybody to pray for our brave soldiers that are in difficult situation. To all that are listening, we're excited about what's ahead. Operator, let's open the call to questions. Operator: [Operator Instructions] And the first question today will be from [ Carl Wright from Lonetown Capital ]. Unknown Analyst: So first question, could you provide some more insight into the global opportunities you mentioned in the quarter? Elissa Shane: Yes. Hi, Carl. Certainly. So the first of the EU registrations on the submission we did came in, so we expect many other EU states to follow suit within the next upcoming months. And with that, we have been positioned with current relationships and distributors from Poland, Germany, Netherlands that have been around our technology and really educated to be able to take on the opportunities that have been waiting for just that registration. So just as the U.K. did once the HSE came through earlier in this quarter with bringing on TCA and quickly being able to fulfill our first custom engineered system, I see that happening with the other regions in the EU. Unknown Analyst: Got it. And then congratulations on bringing down operating expenses by 10%. Could you provide a little more color about how we should think about operating expenses in the business just going forward? Halden Shane: Sure. David, go ahead. David Vanston: Sure. I think the -- again, as Dr. Shane mentioned earlier, as we grow, we will have to invest into our operating expenses, but we already have leverage in it. So we do not expect to see a significant jump in our operating expenses. You should -- if you're going to model it, you would model it as a percentage of revenue growth. But I would say it would slightly decrease as we grow as a percentage. Operator: [Operator Instructions] The next question is coming from John Nelson. John is a private investor. Unknown Attendee: Several questions. First one, I'm one of those long-term investors that... Halden Shane: I know you are. Unknown Attendee: Is -- confident that over the years you're going to deliver. So thank you. Thank you for your... Halden Shane: And I thank you for your help. Unknown Attendee: First question is, you mentioned in the press release in '25 versus '24 revenues, customers deferring, capital expenditure, projects due to uncertain economic environment with the impact of tariffs and Middle East crisis. Are you seeing any signs of -- and you must be seeing some signs of it improving because of your first quarter comments. But are you seeing any of those customers that were deferring CapEx projects starting to move on them? Halden Shane: We are. Unknown Attendee: Okay. And then the BIT Solution revenues for '25 versus '24. Can you provide any details on the comparisons there? Halden Shane: Sure. Are you talking '24 versus '25 or '25 versus '26? Unknown Attendee: No, '24 versus -- '25 versus '24. Halden Shane: Okay. EJ? Elissa Shane: Yes. There's an increase in the solution between '24 and '25, and we're seeing that continue into '26. A lot of it has to go in with Dr. Shan's closing and this moved into open orders. And this came in tandem. About 1.5 years ago, we mentioned a big push on different support services. And having us be able to go on site and speed up the use of our technology and qualify different areas, we're able to predict how much solution they're going to be able to use. So that, in essence, is now finally starting to pay off with them purchasing the orders that they need in advance and just get into more of an auto shipment. So that's the goal, and it's starting to come into play. It started at the end of 2025, and it's moving into this year as well. So that's the big difference. And the 2, why it's referenced in the script that way is because they go in hand. Our support services and our BIT Solution are definitely together in trends. Unknown Attendee: Okay. And then are most of your customers in '25 using more -- significantly more BIT Solution than they did the prior year? Elissa Shane: Yes, definitely. I mean there's always some fluidity to it because you'll have our service provider shift -- if there's -- the fires produced a lot of solution in Q1, different decommissioning of buildings if they get large -- large service contracts, then this definitely increases our solution. So that's a little harder to predict. But when we're able to go in and qualify different spaces or similar to the eye health company where we know how and exactly where they're using the equipment, that's a little easier. But the Q1 of last year certainly was due to some emergency use. So there's definitely an increase in solution. Unknown Attendee: Okay. And then on -- can you provide any more detail as far as how the application would be used to deal with the wing syndrome for honeybees? Elissa Shane: So we do -- we have the study, and we've done a few other lab type studies, and it's definitely a good use, and we're looking and are still speaking with a local university on trying to get live use case. Once we're able to reestablish that and actual application use, it will proceed from there. Halden Shane: So John, I've reached out to the associations, the honeybee associations, domestic, globally. I've reached out to the Board, and I've yet to get a reply and with overwhelming evidence of what we can do and how we can help the pollinators around the world. And right now I'm reaching out to the Department of Agriculture to see if they can help or at least get this technology in front of somebody that wants to make a change. Unknown Attendee: Okay. And then you had mentioned briefly the use for treating marijuana plants? Halden Shane: Right. Unknown Attendee: Is it mites -- or is it for the powdery mildew? Halden Shane: It's for powdery mildew funguses on the plants. We have an EPA label we're trying to get from the EPA just for that. Is that - 4, EJ? Elissa Shane: Yes, that's correct. Unknown Attendee: Okay. And -- but currently, you're not getting any revenues yet from that particular type of usage, correct, because of the need for the EPA label? Halden Shane: I think, EJ, you can answer that. I think there were some... Elissa Shane: There's a handful of customers. With them, it's scaling up. And right now, they're doing a lot of handheld treatments, but we do have a good partner that is promoting our product and even some international interest on the treatment. But we do have some wide use, which is great, and that usually is the first step. Unknown Attendee: Okay. Good. And then one thing that I've been curious about is and whether you've explored or thought about exploring it is uses of SteraMist in the military. And I was thinking about it with regards to the Middle East crisis with all of the Navy ships and the -- in the Gulf and how people are crowded together. It's got to be a potential breathing around for germs and potential infections transfer. So has that -- have you explored that at all or ever talked to the Navy about possible usage of SteraMist? Halden Shane: So the Navy has been -- are they still a customer, EJ? Unknown Attendee: No. Well, are they -- if they are a customer, that's new to me, but have you explored uses with it? And if you have, what response have you gotten from the military? Halden Shane: I think we're a little too small and overwhelmed with everything to go after that at the moment. But I believe there was a testing center that the Navy was involved with. It's a great idea and especially with the new COVID variant that seems to be running around and came from the Netherlands to the U.S., I'm sure that you're right of the close proximity on these ships, they do need to get a disinfectant. And I think this is something that we're going to go look into immediately. Elissa Shane: And we have completed some request for information on the grant government site for military vehicles and how to best implement SteraMist. So they are creating information that way, but that does take quite a bit of time. But we do complete those on a regular basis to get the [indiscernible] out there. Unknown Attendee: Okay. And I don't know if there is a particular certification required, but I was thinking the same thing about SteraMist application possibilities for military hospitals or the VA, which, as we know, has a number of problems with infectious disease transfers. Halden Shane: I think they're waiting for me to answer, John. Elissa Shane: Sorry, I don't -- not anything specific. I think [ almost ] to that. We do have a closed service provider been into military housing, but too early to speak about. Unknown Attendee: Okay. And my -- one of my final questions was going to be on scale up. If you do get a significant amount of new orders, how easy or difficult that would be for you? Halden Shane: Well, it's -- again, we probably need to raise some capital to scale up significantly. The 20 people we have do a hell of a job as a team. We were able to handle COVID pretty much with the same amount of employees, and we did really well. So I think we could handle the immediate scale up depending upon the equipment, but we definitely need to go ahead and increase the size of the company going forward in lots of divisions. Unknown Attendee: Okay. Good. And then last question was a number of -- have you actually total them up as far as the number of new customers added net in '25 versus '24? Halden Shane: I haven't -- David, EJ, have any of you done that? David Vanston: No. Elissa Shane: Not based on new customers, no. Definitely -- individual orders between the years, but... Halden Shane: I think we'll do that, John, and I'll talk about it on the call coming up soon in 6 weeks. Unknown Attendee: Okay. I mean you definitely have listed a number of new names that I hadn't heard on previous calls. So -- but I was just curious about... Halden Shane: Yes, I know. And I left out half of them, too, but it was impossible to go through them all. It's just frustrating to see what happens to the stock and what occurs with the difference. So the point, I think, was well made, and we'll see what goes on. Unknown Attendee: Okay. And then as far -- you've done an excellent job of adding significant distributors, both domestically and internationally. Do you -- is that still a significant part of efforts going forward to add even more distributors? Halden Shane: Absolutely. We're in talks right now with many. Operator: There are no other questions at this time. I would now like to turn the call back to Dr. Halden Shane for closing remarks. Halden Shane: Okay. I just want to thank everybody again and wish everybody a happy Passover and happy Easter. Thank you, operator. Operator: Thank you. This does conclude today's conference. You may disconnect your lines at this time, and have a wonderful day. Thank you for your participation. Halden Shane: You too. Thank you. Before you buy stock in Tomi Environmental Solutions, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tomi Environmental Solutions wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!* Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of May 9, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Tomi (TOMZ) Q4 2025 Earnings Transcript was originally published by The Motley Fool

FREDERICK, Md., May 08, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, today announced financial results for the three months ended March 31, 2026, and provided an update on strategic initiatives. Most significantly, the Company recently announced a non-binding letter of intent to merge with Carbonium Core, Inc., a U.S.-based producer of nuclear-grade graphite for advanced reactor technologies and AI data center infrastructure, representing a transformative new chapter for TOMI. Landmark Post-Quarter Development: Letter of Intent with Carbonium Core, Inc. On April 30, 2026, the Company executed a non-binding letter of intent (the “LOI”) to merge with Carbonium Core, Inc. (“Carbonium Core”), a U.S.-based producer of nuclear-grade graphite for advanced reactor technologies. Carbonium Core will become a wholly owned subsidiary of TOMI upon closing of the proposed transaction (the “Proposed Transaction”). Enterprise Valuation: The enterprise valuation of Carbonium Core implied by the LOI is $120 million, subject to further due diligence. Consideration: In exchange for TOMI acquiring all issued and outstanding shares of Carbonium Core, Carbonium Core stockholders would receive (i) shares of TOMI common stock equal to 19.99% of the Company’s outstanding shares immediately prior to the merger, and (ii) shares of a newly created series of preferred stock convertible into TOMI common stock upon stockholder approval. Strategic Rationale: The Proposed Transaction is intended to diversify TOMI’s business by combining a domestic platform in advanced graphite and lithium materials with the Company’s existing SteraMist® disinfection and decontamination business, including applications for autonomous vehicles (Robotaxis) and battery-operated aerial drones. Carbonium Core’s vertically integrated U.S. production model, including its exclusive purification technology developed in collaboration with Oak Ridge National Laboratory, targets a defensible position in a market dominated by foreign supply. Market Opportunity: Nuclear-grade graphite is a specialty sub-segment of the global graphite market estimated at approximately $13 - $15 billion in 2026, with synthetic graphite, the most directly relevant category, estimated at approximately $8 - $9 billion. U.S. FEOC rules and federal support for advanced nuclear are accelerating demand for non-Chinese-origin graphite. Timeline: Definitive agreements are expected to be signed on or before May 30, 2026, subject to due diligence and stockholder approval, with a 45-day exclusivity period in place. The LOI is non-binding, and the Proposed Transaction is subject to execution of definitive agreements, completion of due diligence, and customary closing conditions including stockholder approval. There can be no assurance that the Proposed Transaction will be consummated on the terms described or at all. First Quarter 2026 Highlights: Revenue Growth: Revenue of $1,654,000 for Q1 2026 represents a 5% increase versus Q1 2025 and a 67% sequential increase over Q4 2025, driven by strong equipment and Custom Engineered System (CES) sales. Applicator Sales Surge: Q1 2026 applicator sales exceeded total full-year 2025 applicator sales, representing a 139% year-over-year increase, reflecting growing adoption of our razor/blade consumable model and the expanding customer install base. BIT™ Solution Momentum: BIT Solution sales grew 21% from 2024 to 2025 and are tracking above 2025 levels in Q1 2026, supporting the Company’s recurring revenue strategy and long-term profitability objectives. Disciplined Cost Management: Total operating expenses declined 15% to $1,458,000 versus $1,706,000 in Q1 2025, reflecting disciplined cost reduction across general and administrative, selling, professional fees, and consulting expenses, while the Company preserved its commercial and technical capacity. Improved Operating Cash Flow: Net cash provided by operating activities was $296,000 for Q1 2026, a $572,000 improvement over Q1 2025, reflecting improved working capital management and growth in deferred revenue from customer deposits. Growing Integration Pipeline: Sales order backlog was $1.7 million as of March 31, 2026. Our integrated project pipeline, encompassing SIS, Hybrid, and CES projects, grew to approximately $4.3 million across 13 customers, up from approximately $3.0 million at year-end 2025. Financial Results for the three months ended March 31, 2026, compared to March 31, 2025 Sales, net was $1,654,000 compared to $1,577,000 for the three months ended March 31, 2026 and 2025, respectively, a 5% increase. Product revenue increased $311,000 (31%), driven by higher equipment and CES-related sales. Service revenue decreased $234,000 (41%), reflecting the timing of decontamination project completions and service engagements in the period. Gross profit was $832,000, or approximately 50% of revenue, for Q1 2026, compared to $952,000, or approximately 60% of revenue, for Q1 2025. The decrease in gross margin reflects strategic price discounts to drive equipment adoption and an unfavorable product mix shift toward lower-margin equipment sales. Management views these factors as temporary, as growth in recurring high-margin BIT Solution consumable and Applicator sales is expected to support margin recovery in future periods. Total operating expenses were $1,458,000 for Q1 2026, a reduction of $248,000 or 15% compared to $1,706,000 in Q1 2025, reflecting lower general and administrative, selling, professional, and consulting costs. Loss from operations was ($626,000) for Q1 2026, an improvement of $128,000 compared to ($754,000) for Q1 2025. Net loss was ($811,000) or ($0.04) per basic and diluted share for Q1 2026, compared to net loss of ($256,000) or ($0.01) per basic and diluted share for Q1 2025. Q1 2025 net loss included a non-recurring Employee Retention Credit of $535,000 and related interest of $83,000. Excluding these one-time items, Q1 2025 adjusted net loss would have been approximately ($874,000), demonstrating meaningful year-over-year operating improvement in Q1 2026. Sales order backlog was $1.7 million as of March 31, 2026, providing strong visibility into near-term revenue conversion. Recent Business Highlights: On January 6, 2026, a private East Coast research university purchased and installed a SteraMist Hybrid System for repeatable, high-level decontamination of reusable medical equipment, representing the second SteraMist Hybrid sale within the Company’s automated installation pipeline. On January 20, 2026, the Company sold a Custom Engineered System in the United Kingdom to an international pharmaceutical manufacturer, integrated into Total Clean Air’s modular cleanroom platform, marking the first deployment of SteraMist iHP technology within TCA’s modular architecture. On February 23, 2026, the UK Health and Safety Executive granted official regulatory authorization for the Company’s BIT Solution and SteraMist iHP products as biocidal products for use in Great Britain and Northern Ireland. On March 3, 2026, the Company entered into a strategic partnership with Total Clean Air, establishing TCA as its Preferred European Partner for SteraMist iHP technology across the United Kingdom and European Union. On March 16, 2026, the Company announced expanded Canadian operations, with its Canadian distribution partner increasing equipment inventory to support direct-to-customer sales across the provinces following strategic placements at leading Canadian health research organizations and hospital systems. On March 18, 2026, the Company announced its expansion into the food safety sector, citing a case study in which SteraMist iHP technology delivered a reduction of up to 95% in sanitation testing costs for a food manufacturer. On March 24, 2026, a major Mexican dairy manufacturer engaged ongoing SteraMist iHP services for facility sanitation through distributor DisinfectCare, extending the Company’s international service footprint. On March 25, 2026, the Company received biocidal product authorization from the Dutch regulatory authority (ctgb), marking TOMI’s first product approval within a European Union member state and supporting a streamlined mutual recognition pathway in other EU member states. On April 30, 2026, the Company signed a Letter of Intent to merge with Carbonium Core, Inc., a U.S.-based producer of nuclear-grade graphite for advanced reactor technologies, with an implied enterprise valuation of $120 million. See “Landmark Post-Quarter Development” above for further details. Executive Commentary Dr. Halden Shane, CEO of TOMI Environmental Solutions commented, “The first quarter of 2026 was a strong start to the year. Revenue grew 5% year-over-year, applicator sales surged 139%, and we cut operating expenses by 15%, all while expanding our regulatory footprint across the EU and UK, growing our integration pipeline to $4.3 million, and winning a $440,000 annual service contract with a leading global medtech company. “Most importantly, on April 30, 2026, we signed a Letter of Intent to merge with Carbonium Core, Inc. This is a transformative step for TOMI. Carbonium Core brings a vertically integrated U.S. production platform for nuclear-grade graphite, a critical strategic material at the nexus of advanced nuclear energy and AI data center demand, with technology developed in collaboration with Oak Ridge National Laboratory. With an implied enterprise valuation of $120 million and a 45-day exclusivity period in place, we are moving forward with focused urgency toward a definitive agreement by May 30, 2026. This transaction has the potential to create substantial long-term value for our shareholders while preserving and growing our SteraMist® franchise. I look forward to updating our shareholders as this process advances.” Looking Ahead TOMI enters the second quarter of 2026 with strong commercial momentum, an expanding recurring revenue base, and a transformative strategic transaction under way. The Company is focused on delivering long-term shareholder value through both its SteraMist® core business and the Proposed Transaction with Carbonium Core. The Company is executing a focused strategy to: Advance the Proposed Transaction with Carbonium Core, Inc. toward definitive agreements and closing, subject to due diligence, regulatory, and stockholder approvals Drive year-over-year recurring revenue growth through increased BIT™ Solution sales, open order policies, and expanded iHP Corporate Service contracts Convert the $4.3 million integration pipeline across 13 active SIS, Hybrid, and CES projects into recognized revenue Continue to grow our international presence through Total Clean Air in the UK and EU, our Canadian distribution partner, and targeted marketing across global regulated markets Leverage EU and UK regulatory authorizations to pursue further market approvals and accelerate European commercial development Pursue additional government, institutional, and life sciences partnerships, including in the compounding pharmacy, food safety, and agricultural biosecurity sectors Conference Call Information TOMI will hold a conference call to discuss First Quarter 2026 results at 4:30 p.m. ET today, May 8, 2026. To participate in the call by phone, dial (888) 506-0062 approximately five minutes prior to the scheduled start time and provide participant access code 776342, or request the "TOMI Environmental Solutions first quarter earnings call." International callers please dial (973) 528-0011. To access the live webcast or view the press release, please visit the Investor Relations section of the TOMI website or register at the following link: https://www.webcaster5.com/Webcast/Page/2262/54004. A replay of the teleconference will be available until May 15, 2026, and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use replay access code: 54004. A replay of the webcast will be available for at least 90 days on the company’s website, starting approximately one hour after the completion of the call. TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at [email protected]. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements regarding the proposed merger with Carbonium Core, Inc., including the likelihood, timing, structure, and valuation of the Proposed Transaction and expected benefit to TOMI; our strategies to grow revenue and expand business development; our expectation with respect to the remainder of 2026, including schedule of delivery, realization of revenue from backlog and pipeline conversion; our ability to generate leads and referrals for sales; the expectation to capture new markets; our ability to improve financial performance; and the statements under the section entitled “Looking Ahead.” The LOI with Carbonium Core is non-binding and there can be no assurance that a definitive agreement will be executed or that the Proposed Transaction will be consummated on the terms described or at all. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expand sales; our ability to maintain and manage growth and generate sales; our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed by us with the SEC, and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. The following represents our condensed consolidated balance sheets and statement of operations from our Quarterly Report on Form 10-Q for the three months ended March 31, 2026:

FREDERICK, Md., May 06, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report results for the first quarter ended March 31, 2026, after the close of the financial markets on Friday, May 8, 2026, and will hold a conference call at 4:30 p.m. ET that day. To participate in the call by phone, dial (888) 506-0062 approximately five minutes prior to the scheduled start time and provide participant access code 776342, or request the "TOMI Environmental Solutions first quarter earnings call." International callers please dial (973) 528-0011. To access the live webcast or view the press release, please visit the Investor Relations section of the TOMI website or register at the following link: https://www.webcaster5.com/Webcast/Page/2262/54004. A replay of the teleconference will be available until May 15, 2026, and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use replay access code: 54004. A replay of the webcast will be available for at least 90 days on the company’s website, starting approximately one hour after the completion of the call. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at [email protected]. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Zach Nevas IMS Investor Relations [email protected]

FREDERICK, Md., April 08, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions is pleased to announce that its preliminary unaudited revenue for the first quarter of 2026 was approximately $1.7 million, reflecting a 67% sequential increase from Q4 2025. Total integrated projects, which encompass projects awaiting capital expenditure approval or signed contracts for our SteraMist Integrated System (SIS), Hybrid, or Custom Engineered System (CES) products have increased to $5.3 million. This pipeline includes 14 customers, with half approved and secured through purchase orders or contracts. To date, first quarter sales combined with current open orders has reached approximately $3,360,000. When compared to Q1 2025 and the previous reporting quarter, Q1 2026 showed increase in preliminary revenue growth across various segments pertaining to operational performance including mobile equipment sales, custom integration deliverables, repairs, and support services. These increases indicate that customers are actively utilizing our equipment and support offerings. By the end of Q1, BIT Solution sales amounted to approximately $427,000, while iHP Corporate Service sales totaled approximately $729,000 in orders that have been delivered or are scheduled for delivery throughout the year. Notably, we secured a $440,000 annual purchase order for decontamination services with a leading global medical technology company. This agreement entails quarterly professional decontamination services utilizing our SteraMist iHP technology. This strategic partnership underlines management's confidence in the ongoing growth trajectory of the iHP Corporate Service business for 2026 and beyond, as highlighted by Dr. Shane during the last earnings call. The client, a global leader in regenerative medicine, neurosurgery, and reconstructive surgery, first engaged TOMI in 2024 for an emergency decontamination deployment executed on short notice. The transition from emergency response to a long-term annual service underscores the client’s commitment to maintaining the highest standards of sterility. The SteraMist iHP service order includes scheduled and validated decontamination services designed to safeguard the integrity of critical cleanrooms and laboratory environments. The first quarter of 2026 witnessed a notable increase in the purchase of standalone applicators utilizing our patented cold plasma arc technology. Sales of these applicators have already surpassed the total sales for the entire previous year, representing a percentage increase of 139%. We remain committed to expanding the availability of applicators linked to delivery systems based on customer preferences, thereby enhancing customer usage and our BIT solution consumable model. The preliminary financial results described in this press release are unaudited and subject to customary adjustments and completion of the quarterly closing process. The Company expects to file its full financial results for its first quarter 2026 in due course, along with the filing of its Quarterly Report on Form 10-Q with the Securities and Exchange Commission. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at [email protected]. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to preliminary financial results, including preliminary revenue information, estimated open orders and estimated total integration pipeline, expected revenue growth in 2026 and beyond, TOMI’s products and services to serve the life sciences sector, and the ability to complete delivery of products and services pursuant to purchase orders. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These may include, but are not limited to, our ability to acquire new customers and expands sales; our projected revenue and revenue recognized from anticipated future purchase orders, invoiced orders, and contracts, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Zach Nevas IMS Investor Relations [email protected]